Livzon Pharmaceutical Group's (SZSE:000513) Shareholders May Want To Dig Deeper Than Statutory Profit
Livzon Pharmaceutical Group's (SZSE:000513) Shareholders May Want To Dig Deeper Than Statutory Profit
Livzon Pharmaceutical Group Inc.'s (SZSE:000513) robust recent earnings didn't do much to move the stock. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.
立营药业集团股份有限公司(SZSE:000513)最近强劲的盈利并没有对股票产生太大影响。我们相信股东已经注意到一些超出法定利润数字之外的担忧因素。
How Do Unusual Items Influence Profit?
非常规项目如何影响利润?
Importantly, our data indicates that Livzon Pharmaceutical Group's profit received a boost of CN¥199m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).
重要的是,我们的数据显示,立营药业集团的利润在过去一年中因飞凡项目获得了19900万元人民币的提振。虽然我们喜欢看到利润增长,但当飞凡项目做出重大贡献时,我们通常会更加谨慎。当我们分析了成千上万家上市公司的数据后,我们发现,某一年中由飞凡项目带来的提振往往不会在下一年重复出现。毕竟,这正是会计术语所暗示的。假设这些飞凡项目在当前年度不再出现,那么我们预计明年的利润会较弱(在没有业务增长的情况下)。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。
Our Take On Livzon Pharmaceutical Group's Profit Performance
我们对立营药业集团的利润表现看法
Arguably, Livzon Pharmaceutical Group's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Livzon Pharmaceutical Group's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 18% per annum growth in EPS for the last three. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. At Simply Wall St, we found 1 warning sign for Livzon Pharmaceutical Group and we think they deserve your attention.
可以说,立卓药业集团的法定收益被飞凡项目扭曲,提振了利润。因此,我们认为立卓药业集团的法定利润可能比其潜在盈利能力更好。但至少持有者可以从过去三年每股收益每年增长18%中得到一些安慰。最终,如果您想正确了解该公司,则有必要考虑不仅仅是以上因素。因此,如果您想深入研究这支股票,关注它面临的任何风险是至关重要的。在Simply Wall St,我们发现立卓药业集团存在1个警告信号,我们认为这是值得您注意的。
Today we've zoomed in on a single data point to better understand the nature of Livzon Pharmaceutical Group's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天,我们聚焦于一个数据点,以更好地了解立卓药业集团利润的性质。但还有许多其他方法可以帮助您形成对公司的看法。一些人认为高股权回报率是优质企业的良好迹象。虽然这可能需要您做一些研究,但您可能会发现这个免费的公司收集股权回报率高的公司,或者这份具有重要内部持股的股票清单对您有所帮助。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。